<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04361812</url>
  </required_header>
  <id_info>
    <org_study_id>HS632-I</org_study_id>
    <nct_id>NCT04361812</nct_id>
  </id_info>
  <brief_title>Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Parallel Controlled，Single-dose Phase I Study Comparing the Pharmacokinetic and Safety Similarities of Recombinant Anti IgE Humanized Monoclonal Antibody (HS632) With Omalizumab a in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the bioequivalence of HS632 and Omalizumab (Xolair®) in a single subcutaneous&#xD;
      administration in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, parallel controlled，single-dose phase I&#xD;
      study to compare the pharmacokinetic and safety similarities of recombinant anti IgE&#xD;
      humanized monoclonal antibody (HS632) With omalizumab a in Chinese healthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0 -∞) of single subcutaneous administration of HS632 and Xolair in healthy subjects</measure>
    <time_frame>13weeks</time_frame>
    <description>Area Under the concentration-time Curve from time zero to infinity of single subcutaneous administration of HS632 and Xolair in healthy subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of single subcutaneous administration of HS632 and Xolair in healthy subjects Peak plasma concentration (Cmax) after single subcutaneous administration of HS632 and Xolair in healthy subjects</measure>
    <time_frame>13weeks</time_frame>
    <description>Maximum serum concentration (Cmax) of HS632 and Xolair in healthy subjects Peak plasma concentration (Cmax) after single subcutaneous administration of HS632 and Xolair in healthy subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC (0 - t) of HS632 and Xolair in single subcutaneous administration in healthy subjects</measure>
    <time_frame>13weeks</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) from 0 to the last selected time point, i.e. 2184h after the injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2.Tmax of single subcutaneous administration of HS632 and Xolair in healthy subjects</measure>
    <time_frame>13weeks</time_frame>
    <description>Time to Cmax (Tmax) of single subcutaneous administration of HS632 and Xolair in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3.CLt/F of single subcutaneous administration of HS632 and Xolair in healthy subjects</measure>
    <time_frame>13weeks</time_frame>
    <description>Total clearance corrected by bioavailability (CLt/F) of single subcutaneous administration of HS632 and Xolair in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2) of single subcutaneous administration of HS632 and Xolair in healthy subjects</measure>
    <time_frame>13weeks</time_frame>
    <description>Half-life (T1/2) of single subcutaneous administration of HS632 and Xolair in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of single subcutaneous administration of HS632 and Xolair in healthy subjects</measure>
    <time_frame>13weeks</time_frame>
    <description>Apparent volume of distribution corrected by bioavailability (Vd/F) of single subcutaneous administration of HS632 and Xolair in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events[Safety]</measure>
    <time_frame>13weeks</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events [Safety] of distribution corrected by bioavailability (Vd/F) of single subcutaneous administration of HS632 and Xolair in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of single subcutaneous administration of HS632 and Xolair in healthy subjects</measure>
    <time_frame>13weeks</time_frame>
    <description>Anti drug antibody（ADA）of single subcutaneous administration of HS632 and Xolair in healthy subjects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Similarity of Pharmacokinetics and Safety</condition>
  <arm_group>
    <arm_group_label>HS632</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HS632 150mg for a single subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omalizumab (Xolair®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omalizumab 150mg for a single subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HS632</intervention_name>
    <description>Subcutaneous injection of HS632</description>
    <arm_group_label>HS632</arm_group_label>
    <other_name>Recombinant anti IgE humanized monoclonal antibody 150mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab (Xolair®)</intervention_name>
    <description>Subcutaneous injection of Omalizumab Xolair®)</description>
    <arm_group_label>Omalizumab (Xolair®)</arm_group_label>
    <other_name>Omalizumab 150mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Signing the informed consent and being able to complete the test according to the&#xD;
             plan;&#xD;
&#xD;
          -  2.Age ≥ 18 and ≤ 40 (subject to the date of signing the informed consent), male;&#xD;
&#xD;
          -  3.The body mass index (BMI) is between 20and6 kg / m2 (including 20 kg / m2 and 26 kg&#xD;
             / m2), and the body weight is between 50-75 kg (including 50 kg and 75 kg);&#xD;
&#xD;
          -  4.The subject (including the partner) has no plan of pregnancy from the date of&#xD;
             signing informed consent to 6 months after the administration of the experimental drug&#xD;
             and is willing to use effective contraceptive methods, such as abstinence, oral&#xD;
             contraceptives, iUDs or double barrier methods (e.g., condom plus diaphragm)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Patients with mental, respiratory, cardiovascular, digestive, urinary, reproductive,&#xD;
             skeletal and motor, blood, endocrine, nervous and other system diseases, or patients&#xD;
             with any previous immune diseases;&#xD;
&#xD;
          -  2.Patients with severe bleeding factors affecting venous blood collection&#xD;
&#xD;
          -  3.Skin diseases or other diseases affecting subcutaneous injection;&#xD;
&#xD;
          -  4. Patients with upper respiratory tract infection or other acute infection in the 2&#xD;
             weeks prior to screening;&#xD;
&#xD;
          -  5.Patients with history of malignant tumor;&#xD;
&#xD;
          -  6.Those who have undergone surgery within two months before signing the informed&#xD;
             consent;&#xD;
&#xD;
          -  7.Drinking more than 14 units of alcohol per week (14 bottles of 360 ml beer or 630ml&#xD;
             of 40% spirits or 2100ml of wine) within 6 months before screening, or those with&#xD;
             positive results of alcohol breath test;&#xD;
&#xD;
          -  8.Those who have used soft drugs (e.g., marijuana) within 3 months prior to signing&#xD;
             the informed consent or hard drugs (e.g., cocaine, phencyclidine, etc.) within 1 year&#xD;
             prior to the trial； those who have positive drug abuse test results (morphine,&#xD;
             methamphetamine, ketamine, MDMA, tetrahydrocannabinolic acid, cocaine);&#xD;
&#xD;
          -  9. Those who are addicted to smoking or smoke more than 5 cigarettes per day on&#xD;
             average in the 3 months before signing the informed consent; or those who have&#xD;
             positive nicotine results;&#xD;
&#xD;
          -  10.Those who have a history of drug or food allergy, or who have special requirements&#xD;
             for diet and cannot abide by the unified diet or specific allergy history (asthma,&#xD;
             urticaria, eczema dermatitis, etc.); those who have allergic rhinitis, or are known to&#xD;
             be allergic to any component of the test drug or latex (contained in the syringe&#xD;
             needle cover);&#xD;
&#xD;
          -  11.Those who drinking too much tea, coffee and / or caffeinated beverages (more than 8&#xD;
             cups, 1 cup = 250 ml) every day;&#xD;
&#xD;
          -  12. Those who have received any drug treatment (including prescription drugs,&#xD;
             over-the-counter drugs, biological products, Traditional Chinese medicine, vitamins,&#xD;
             dietary supplements, etc.) and health care products within 14 days before signing the&#xD;
             informed consent;&#xD;
&#xD;
          -  13. Traditional Chinese medicine (except proprietary Chinese Medicine) and health care&#xD;
             products are planned to be used during the test;&#xD;
&#xD;
          -  14. Have a blood donation history within 3 months before signing the informed consent,&#xD;
             or plan to donate blood during the trial;&#xD;
&#xD;
          -  15. Those who plan to accept any biological drugs within 3 months after the&#xD;
             administration of the test drug or those who plan to accept monoclonal antibody drugs&#xD;
             within 9 months;&#xD;
&#xD;
          -  16. Those who plan to donate sperm within 6 months after the administration of the&#xD;
             test drug;&#xD;
&#xD;
          -  17. Those who plan to undergo (including cosmetic surgery, dental surgery and oral&#xD;
             surgery) during the trial period;&#xD;
&#xD;
          -  18. Those who plan to take part in strenuous exercise during the experiment, including&#xD;
             physical contact exercise or collision exercise;&#xD;
&#xD;
          -  19. Participants in other clinical trials within 3 months before signing the informed&#xD;
             consent;&#xD;
&#xD;
          -  20. Vaccinated within 6 months before signing the informed consent;&#xD;
&#xD;
          -  21. In the screening period or baseline period, the researchers think that the&#xD;
             physical examination and laboratory examination of the subjects have clinical&#xD;
             significance abnormalities; or the following indicators exceed the following&#xD;
             standards: the rate of pulse in awake state is less than 50 times / min or more than&#xD;
             100 times / min, the systolic pressure in sitting position is equal to or more than&#xD;
             140 mmHg or the diastolic pressure is more than 90 mmHg, and the ear temperature is&#xD;
             more than 37.5 ℃; any one of eosinophil, neutrophil, platelet is beyond the normal&#xD;
             range; eGFR is less than 90 mL / min / 1.73m2 (estimated by MDRD formula of kidney&#xD;
             disease diet improvement test, see Annex I);&#xD;
&#xD;
          -  22. Patients with clinically significant ECG abnormalities in screening or baseline&#xD;
             period, or with QTcF ≥ 450 ms, or with a history of clinically significant ECG&#xD;
             abnormalities in the past;&#xD;
&#xD;
          -  23. The results of chest X-rayor chest CT examination or B-ultrasonic examination are&#xD;
             clinically significant abnormalities according to the judgment of the researcher;&#xD;
&#xD;
          -  24.Any one of HIV antibody, HBsAg, HBeAg, HBcAg, HCV antibody and Treponema pallidum&#xD;
             antibody is positive;&#xD;
&#xD;
          -  25. The researchers think those who are considered by the investigator unsuitable for&#xD;
             the trail or who may not be able to complete the trial for other reasons is not&#xD;
             suitable to be enrolled or may not be able to complete the experiment for other&#xD;
             reasons;&#xD;
&#xD;
          -  26. Employees or relatives of researchers, research centers, sponsors and contract&#xD;
             research organizations.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Zhang, Dr. Pharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaojie Wu, Dr. Pharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anhui Peng, master</last_name>
    <phone>18806555071</phone>
    <email>anhui.peng@hisunbioray.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui Peng</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Anhui Peng, master</last_name>
      <phone>18806555071</phone>
      <email>anhui.peng@hisunbioray.com.cn</email>
    </contact>
    <investigator>
      <last_name>Jing Zhang, Dr. Pharm</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaojie Wu, Dr. Pharm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>August 20, 2020</last_update_submitted>
  <last_update_submitted_qc>August 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

